(New York, NY) The first areas to show signs of aging are the regions around the eyes and forehead. Drooping of the skin on the brows and of the eyebrows themselves can be due to loose skin and fat loss around the brow, forehead and temples. Age, sun damage, and furrowing of the brow can also create wrinkles. A common procedure, the brow lift, also called a forehead lift, can improve all these problems and produce a younger, more refreshed look.

Until now, the gold standard in lifting the brow and forehead in brow lift surgery has been by utilizing sutures or Endotines. Now with the introduction of BioGlue® Surgical Adhesive, surgeons can perform a less invasive brow lift with a faster, more comfortable recovery time.

Joseph Eviatar, MD, board certified Ophthalmologist and Oculoplastic Surgeon at Chelsea Eye and Cosmetic Surgery Associates in New York City, is one of the investigators for BioGlue® and is involved in an FDA clinical trial. According to Eviatar, “So far, BioGlue® has been approved for use in cardiac and vascular reconstructive surgery. We are working to get approval for use of BioGlue® in cosmetic procedures such as endoscopic brow lifts where it has really proved to make a difference.”

BioGlue® is a two-component adhesive that creates a flexible, mechanical seal, independent of the body’s clotting mechanism, within 20 to 30 seconds, and reaches its maximum bonding strength in two to three minutes. Dr. Eviatar utilizes the BioGlue® to fixate the brow when performing endoscopic and transblepharoplasty brow lifts. Fewer incisions or “holes” are made when using this surgical adhesive as sutures, Endotines and screws are not needed. “There is no foreign device left in the body and BioGlue® gets absorbed by the body within a few months,” adds Eviatar.

CryoLife, Inc.
800.438.8285
www.cryolife.com

Source: CryoLife

Elemé Medical Inc., a private venture-backed aesthetics company building a franchise in the body shaping market with an initial focus on treatment of cellulite, announced that it has raised $18 million in a “Series C” financing led by L Capital Partners- www.lcapitalpartners.com.

The C round also included new investor Hambrecht & Quist Capital Management (www.hqcm.com), as well as returning investors Three Arch Partners (www.threearchpartners.com) and EDF Ventures (www.edfvc.com). The funds will be used to commercialize the Company’s FDA-cleared SmoothShapes® System and also to develop the Company’s pipeline of body shaping technologies. Ting Pau Oei, a partner at L Capital Partners, and Daniel R.Omstead, Ph.D., President and CEO of Hambrecht & Quist Capital Management, will join the board of directors of Elemé Medical.

The SmoothShapes® System uses a proprietary technology called Photomology® to treat the underlying causes of cellulite. Thermal and non-destructive, Photomology’s unique mechanism of action combines dynamic laser and light energy with mechanical massage and vacuum to specifically affect the underlying tissue responsible for the visible manifestations of cellulite. Results include improved appearance of cellulite with tighter, smoother skin that patients can see and feel.

“The fact that we have raised a significant round of financing from sophisticated investors in a down market bears strong testimony to the validity of our approach to treating cellulite,” said Nancy M. Briefs, President and CEO. “We have said all along that our claims about SmoothShapes are based exclusively on results obtained in rigorous, independent and ongoing clinical studies of the System. Indeed, the due diligence conducted by our new investors and their ensuing investment in Elemé Medical further substantiates our technology’s robust scientific foundation.”

“We are intrigued by the immense size of the potential market for the SmoothShapes device,” explained lead investor L Capital Partners’ Ting Pau Oei, who spent 22 years prior to joining L Capital Partners at Johnson & Johnson, the last 12 at JJDC, Johnson & Johnson’s venture capital arm. “Equally important, Elemé Medical’s pipeline of other patented technologies is considerable, with 35 issued patents in the portfolio, thereby providing a very substantial barrier to entry in the body shaping sector.“

About Elemé Medical
Elemé Medical Inc., headquartered in Merrimack, N.H., is dedicated to providing market-leading technology in all areas of body contouring. Its SmoothShapes® System, a medical device with FDA clearance to market, launched in spring 2008.

Elemé Medical, Inc.
603.816.1920
www.elememedical.com

Source: Elemé Medical, Inc.

Smile Reminder Service Uses Real Time Messaging to Keep Botox Patients Informed, Updated and On-Time

Lehi, UT – August 6, 2008, 2008 – Smile Reminder, which is now being used by medical spas, plastic surgeons and dermatologists, allows patients to communicate directly with their doctor or esthetician via text messaging or email, sending them personalized reminders about their upcoming Botox appointments. When Botox patients haven’t scheduled a follow-up visit, Smile Reminder’s “recare” feature automatically sends a friendly notice, reminding them that if they don’t return soon, their wrinkles surely will. The “recare” reminders generate revenue that could otherwise be lost, while simultaneously providing patients a much appreciated service.

Days after treatment, Botox patients see wrinkles disappear right before their eyes. (As well as right above their eyes, right below their eyes…) But with so much competition, Smile Reminder’s “recare” service ensures their return to the same doctor or esthetician for repeat business. The Smile Reminder service makes the process of booking return office visits as smooth as the patient’s new complexion.
Not only does Smile Reminder serve as a convenient tool for customers, but it also enables doctors to send birthday or holiday greetings, group messaging and updates on last minute cancellations. Smile Reminder takes the worry (and the worry lines) out of confirming appointments. The result: extra time for the staff to handle more important business.

“Scheduling office visits is time consuming for both the patient and staff,” says Smile Reminder CEO Jim Higgins. “Smile Reminder gives doctors and estheticians a direct route of communication while concurrently giving patients access to all pertinent information. This enhanced experience allows both doctors and patients to benefit equally. The end result is time saved and revenue generated.”
With Smile Reminder, doctors can instill in their patients the kind of convenience and comfort they deserve when scheduling each upcoming procedure. The “recare” feature provides patients helpful reminders as well as helping doctors and estheticians to obtain additional revenue, giving both parties a little something more to smile about.

ABOUT SMILE REMINDER
Smile Reminder, the pioneer in text and email messaging to patients, is the clear leader in providing patient communication and interaction solutions for health-care providers.

Smile Reminder’s patent-pending solution enables practices to increase revenue, streamline efficiencies and build patient loyalty. Based on purpose-driven technology, Smile Reminder equips practices with a “high-tech” solution that does not sacrifice the “high-touch” personalization when communicating with patients. Smile Reminder messaging solutions include every type of personalized patient e-communication including appointment reminders, confirmations, “recare”/recall, new patient referrals, birthday wishes, holiday wishes, surveys, newsletters, customized promotions and more. Smile Reminder enhances its messaging solution with SmileDash.com, an online patient interaction suite. Patients can now interact with their provider online in a secure environment to pay bills, view patient images, send secure messages, download forms, and more.

Smile Reminder
866.605.6867
www.smilereminder.com

Source: Smile Reminder

First portable CO2 fractional handpiece converts CO2 lasers into a fractional system with treatment options capability

Cherry Hill, NJ – August 06, 2008 – LaserTight LLC announced today the company will be showcasing the first portable CO2 fractional handpiece, SelectScan, at four major medical trade shows, scheduled to be held this fall.

A LaserTight spokesperson stated that the SelectScan portable fractional hand piece offers physicians a cost-effective way to convert their CO2 lasers into a fractional system. The conversion enables the CO2 owner to offer a wider array of services including the ability to meet patient demand for the popular fractionated procedures.

A distinct advantage of the SelectScan portable fractional hand piece, according to the company, is that it affords the physician the option of choosing the best applicable treatment parameters from among 8 different scan patterns. Based on patients’ needs and available recovery time, the SelectScan portable fractional hand piece can be used for procedures ranging from micro-ablative to conventional deep ablative. The deeper dermal penetration scanning mode removes unwanted skin cells and wrinkles while simultaneously effecting long-term remodeling of collagen.

Still recognized as the gold standard for facial rejuvenation and tissue tightening CO2 ablative procedures have, however, declined in popularity over the past few years, in part due to the post-procedure downtime patients experience.

Conversely, fractional CO2 resurfacing is rapidly growing in popularity. In this procedure the laser beams ablate defined miniscule areas without damaging the surrounding skin. The fact that the entire epidermis is not ablated accounts for the rapid healing time; and, the skin not targeted by the laser beams triggers a natural healing process that effects skin tightening and promotes collagen genesis.

SelectScan CO2 fractionated treatment is a 30 minute in-office procedure requiring only topical anesthetic. FDA cleared, the SelectScan CO2 portable fractional hand piece uses no consumables and has been used on over 500 patients.

About LaserTight LLC
LaserTight™ is a developer and seller of FDA cleared laser devices for medical and aesthetic applications. The company offers a range of products that include LaserTight and SelectScan™ along with extensive product support systems that include training, continuing education, physician networking, and product servicing.

LaserTight LLC
856.216.2280
www.lasertight.com

Source: LaserTight LLC

Herzliya, Israel and Morris Plains, NJ − The U.S. Food and Drug Administration (”FDA”) today announced the approval of EVOLENCE® for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds. EVOLENCE® is a new advanced collagen-based structural dermal filler, and a first of its kind product. The introduction of EVOLENCE® marks the first dermal filler entry for the Aesthetics Group of OrthoNeutrogena. While new to the United States, EVOLENCE® has been available in other markets such as in Canada, Western and Eastern Europe, Israel, South Korea and Russia since 2004.

“EVOLENCE® represents a new generation of facial fillers, an innovative structural agent providing beautiful, immediate results by replacing the collagen lost with long-lasting, naturally sourced collagen,” said Annie Heremans, M.D., Ph.D., Vice President, responsible for the Company’s research and development of the Medical and Aesthetic Dermatology franchises. “We are pleased to enter the U.S. aesthetic space with a differentiated dermal filler designed for optimal patient outcomes. Given our rich heritage in skin care and and commitment to science, we anticipate EVOLENCE® will be a welcome addition to current aesthetic treatment options.”

EVOLENCE® will be introduced throughout the second half of 2008, in coordination with physician training, to ensure optimal patient satisfaction and outcomes.

EVOLENCE® represents a breakthrough in aesthetics. As one of nature’s most fundamental and abundant building blocks, collagen comprises up to 80% of the dermis and it helps maintain skin strength, structure and support. Collagen naturally breaks down as a person ages, leading to the appearance of wrinkles, lines and folds.

EVOLENCE®, and its proprietary GLYMATRIX™ Technology, uses naturally sourced collagen to replace the body’s lost collagen, adding volume and structural support in depleted areas, for a more naturally youthful appearance. In addition, no pre-test is needed, and GLYMATRIX™ Technology delivers longer-lasting durability than previous collagen dermal fillers.

Results are visible and immediate at the time of treatment, with minimal to no bruising or swelling, allowing physician and patient to gauge the amount of wrinkle correction with more precision. EVOLENCE® is recommended for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds, to be injected in the mid-to-deep dermis.

“We now have a collagen filler that does not require a pre-test and delivers immediate, beautiful and
natural-looking results that last with minimal to little downtime for the patient,” said Z. Paul ” said Z. Paul Lorenc, M.D., F.A.C.S., Assistant Professor of Surgery, New York University School of Medicine and Principal Investigator on the EVOLENCE® U.S. pivotal study. “EVOLENCE® consistent and predictable results for all patients with every treatment.”
About EVOLENCE®

EVOLENCE® is an advanced collagen-based structural dermal filler that provides long-lasting treatment of moderate to deep facial wrinkles and folds, such as nasolabial folds. The results of treatment with EVOLENCE® are immediate, with little to no downtime post-treatment and clinically proven to last through six months. Additional data for 12-month duration approval is being filed with the FDA.

Unlike other dermal fillers that use hyaluronic acid (HA), which absorb water to create their effect, EVOLENCE® is a true structural agent due to its three-dimensional collagen matrix. This collagen structure benefits patients as it is directly linked to the minimal bruising and swelling that might result. EVOLENCE® does not use chemicals for cross-linking like many other products do, but instead uses natural sugar to improve durability. EVOLENCE® collagen is cross-linked through its patented GLYMATRIX™ Technology using the natural sugar, D-Ribose. The GLYMATRIX™ process is designed to:

- Mimic naturally occurring collagen in the skin by creating a true structural framework with natural, durable cross-links to ensure filler longevity
- Provide consistent and predictable results
- Use natural ingredients for natural-looking results

The naturally sourced porcine collagen used in EVOLENCE® is the most genetically similar to human collagen and has been used safely and effectively for decades in various medical applications, including heart valve replacement.

This new generation collagen filler is intended for injection into the mid-to-deep dermis for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds. The most common side effects of EVOLENCE®injections are usually injection-site related and include mild swelling, redness, and pain. Other rare side effects include the development of small areas of firmness under the skin at the treated sites that may be noticed when the areas are pressed upon.

EVOLENCE®® has undergone rigorous testing and has been demonstrated to be safe and effective through clinical studies. For more information on the product, visit www.evolence.com.
About OrthoNeutrogena, Aesthetics Group

EVOLENCE® is marketed in the United States by the Aesthetics Group of OrthoNeutrogena, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and part of the Johnson & Johnson family of companies. This innovative collagen structural dermal filler was developed by ColBar LifeScience, Ltd., a biotechnology company specializing in reconstructive medicine and tissue engineering. The company has perfected a technique in which collagen, a main building block of living organisms, can be purified and transformed so as to create a variety of products that are structurally stable and safe for medical applications. ColBar LifeScience Ltd., is also subsidiary of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Aesthetics Group of OrthoNeutrogena
800.EVOLENCE (386-5362)
www.evolence.com

Source: OrthoNeutrogena

Brightens and Minimizes Discoloration of Facial Skin
Provides a More Refined, Resurfaced and Illuminated Facial Texture

San Jose, CA – Jan Marini Skin Research, Inc. (JMSR; www.janmarini.com) introduces Age Intervention Enlighten, a remarkable new composition that brightens and encourages the uniform appearance of facial discoloration — even stubborn hyperpigmentation.

“Women often associate fine lines and wrinkles with aging but discoloration is an even more visual sign of the aging process,” explains Jan Marini, president and CEO of Jan Marini Skin Research. “Age Intervention Enlighten is an exceptional brightening technology with de-aging agents that result in refined, rejuvenated and illuminated skin.”

Uneven skin tones and discoloration can age the look of facial skin just as dramatically as lines and wrinkles. Overly pigmented facial areas that may occur due to melasma, cumulative sun exposure and ethnicity are some of the most common and difficult to concerns to treat.

Enlighten contains a combination of two exceptional topical agents that address the appearance of facial discoloration. Enlighten also includes Retinol, a superior retinoid that discourages the production of excess melanin and assists in resolving the appearance of existing facial discoloration. The Retinol also acts as a potent anti-aging tool that provides a more refined, resurfaced and illuminated facial texture.

Enlighten’s exceptional brightening technology and de-aging agents result in the refined, rejuvenated and illuminated skin we all want.

Age Intervention Enlighten is offered in a 1 oz. pump bottle.

Jan Marini Skin Research
408.362.0130
www.janmarini.com

Source: Jan Marini Skin Research

Technology designed to selectively weaken specific muscles may provide an attractive alternative treatment for frown lines

San Mateo, CA – BioForm Medical, Inc. (NASDAQ: BFRM) announced that it has acquired substantially all of the assets of privately-held, Denver, CO based, Advanced Cosmetic Intervention, Inc. (ACI) and associated technology rights for $12 million cash, plus future royalties and a potential sales-related milestone. This acquisition provides BioForm Medical, a leading medical aesthetics company, with a commercially-available technology for local nerve ablation.

ACI’s device, sometimes also referred to as the GFX device in prior media reports, is currently cleared via a 510(k) by FDA to create RF heat lesions in nerve tissue. The ACI device uses minimally-invasive bi-polar radiofrequency energy selectively to weaken nerve signal transduction with durable effects.

The use of this technology on nerves that control the muscles of the forehead may reduce the appearance of frown lines, or glabellar furrows. BioForm Medical expects to conduct clinical studies specifically intended to support an FDA application seeking clearance to market this product for the treatment of frown lines. The Company expects to also seek a CE mark and certain other international registrations of the ACI device for aesthetics indications.

“We are building a leading medical aesthetics company. We believe this new treatment will offer patients an attractive alternative therapy for the treatment of frown lines. Many patients in our consumer research surveys have indicated that they choose not to receive neurotoxin treatment due to fear of losing facial expressions, or fear of injections with a toxin,” stated Steven Basta, CEO of BioForm Medical. “We believe that the synergy of this product with our Radiesse dermal filler will be terrific. We have a differentiated, long-lasting filler, and in the coming years we hope to offer physicians a new treatment option for frown lines. This is part of our commitment to partnering with physicians to offer them improved aesthetic treatment options that can grow their practices.

This device could appeal to many of the same physicians who select Radiesse dermal filler for their patients, and will leverage our existing sales and marketing organization.” In the acquisition of ACI, BioForm Medical will hire several of ACI’s employees, and retain others as consultants to maintain continuity of this program and to accelerate future product development and commercialization activities. In addition to the up-front consideration, BioForm Medical will pay a single-digit royalty to ACI. The Company anticipates that significant positive revenue impact of this acquisition is not likely until it obtains clearance for the product for aesthetic applications, anticipated to occur in calendar year 2009.

About BioForm Medical, Inc.
BioForm Medical, Inc. is a medical aesthetics company headquartered in San Mateo, California. BioForm is dedicated to bringing doctors and their patients safe and effective products for use in the dermatology, plastic surgery and ENT markets. BioForm’s products include Radiesse®, a long lasting filler for use in facial aesthetics and vocal fold insufficiency, and Coaptite® for treating female stress urinary incontinence which is marketed through a partnership with Boston Scientific Corporation. BioForm has licensed U.S. marketing rights to Aethoxysklerol®, the worldwide leading sclerotherapy agent, which is currently being evaluated in a Phase III clinical trial. BioForm has also licensed BioGlue, a new surgical adhesive product for plastic surgery applications, which is being developed in a partnership with CryoLife, Inc.

BioForm Medical Inc.
866.862.1211
www.bioform.com

Source: BioForm Medical Inc.

BURLINGTON, Mass. - Palomar Medical Technologies Inc. (Nasdaq: PMTI), a leading researcher and developer of light- based systems for cosmetic treatments, announced the unveiling its latest innovation in aesthetic laser technology at the 28th annual conference of the American Society for Laser Medicine & Surgery (ASLMS) in Kissimmee Florida, April 2-6. Palomar displayed a new platform called the Aspire(TM) aesthetic laser platform and Stylus(TM) Sculpter laser-assisted liposuction handpiece in booth #507 in the ASLMS exhibit hall. The Aspire platform will allow Palomar to offer solutions to new procedures which are in high-demand including laser-assisted liposuction. The Aspire platform will complement the broad range of aesthetic applications offered by Palomar’s flagship StarLux(R) 500 laser and pulsed-light platform.

Traditional liposuction is one of the most commonly performed plastic surgery procedures, according to the 2007 survey from the American Society of Aesthetic Plastic Surgery. Laser-assisted liposuction holds out the promise for a better technique due to the laser’s ability to quickly and selectively melt fat and heat surrounding tissue. Palomar’s approach to laser-assisted liposuction with the Aspire platform and Stylus Sculpter handpiece is to utilize unique tip designs and selective and efficient wavelengths for melting fat and providing the desired thermal effects on surrounding tissue.

Chief Executive Officer Joseph P. Caruso commented, “The unveiling of the Aspire platform and Stylus Sculpter handpiece is the culmination of years of research directed to absorption of light by fat. Our system uses optimal wavelengths to melt fat and provide the appropriate amount of heat to the surrounding tissue. As with all Palomar products, the Aspire platform is based on sound scientific principles developed and tested by Palomar’s research and development organization, which is preeminent in the light-based aesthetic industry.”

Mr. Caruso continued, “The Aspire platform is an ideal complement to the StarLux platform for providing opportunities for even more treatment modalities. With the new aesthetic procedures that will be possible with Aspire, and the many popular treatments, including hair removal, skin rejuvenation and skin resurfacing, available with the StarLux(R) 500, practitioners will be able to offer a complete suite of the most-requested aesthetic procedures.”

The Aspire Platform and Stylus Sculpter liposuction laser-assisted handpiece are pending FDA clearance and should be available for shipment in the third quarter 2008.

About Palomar Medical Technologies Inc.
Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the- counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. Palomar has granted The Procter & Gamble Company a non-exclusive License Agreement to certain patents, technology and FDA documents related to the home-use, light-based hair removal field for women. In addition, Palomar has an exclusive development and license agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

Palomar Medical
800.PALOMAR (725.6627)
www.palomarmedical.com

Source: Palomar Medical

Bio-Therapeutic is pleased to release the bt-analyze™ skin identification system. Part of Bio-Therapeutic’s bt-gear™ line, the bt-analyze™ provides an accurate and essential assessment of the skin’s moisture contents.

The bt-analyze™ is tiny in price and size, but large on performance. Measuring less than 3.5 inches in length the bt-analyze™ weighs less than ¼ of a pound and holds a minuscule price of $95 making it an ideal fit for all forward thinking technologists looking to get their tech on!

Bio-Therapeutic, Inc., the world leader in anti-aging technology, was established in 1974, and is headquartered in Seattle, Washington. With worldwide distribution, Bio-Therapeutic supplies skin therapists with the most cutting edge, age defying technology available today including the Bio-Ultimate Platinum® microcurrent system, Bio-Synthesis™ light activated rejuvenation system, Bio-Oxygen™ oxygen infusion system, Bio-Brasion™ microdermabrasion system, Bio-Dermology™ cellulite system, and bt-GEAR™ Tools and Technology of Convenience. The company is a FDA and ISO registered device manufacturer, and all equipment is safety tested and UL/CSA listed. Ongoing clinical trials with the University of Washington ensure proven efficacy and results.

Bio-Therapeutic
800.971.6438
www.bio-therapeutic.com

Source: Bio-Therapeutic

Artes Medical plans to restructure but will still expand its ArteFill sales force

NEW YORK (Associated Press) - Medical technology company Artes Medical Inc. said it is restructuring in an effort to reduce costs in line with expected revenue.

The company said the goal is to “re-align” its overall cost structure toward its prior 2008 revenue guidance of $13 million to $16 million. Meanwhile, it will continue expanding its sales force for the injectable implant ArteFill, which is used as a wrinkle treatment.

Artes said it believes it has enough cash, along with anticipated ArteFill sales, to fund the company through the first quarter of 2009.

Shares of Artes fell 8 cents, or 6.7 percent, to close at $1.12.

Artes Medical
888.ARTEFILL (278.3345)
www.artesmedical.com

Source: CNN Money

Canfield Imaging Systems premieres its latest product: the Reveal™ Imager

Canfield Imaging Systems is now offering the Reveal™ Imager, its latest facial imaging system for skin care professionals. The Reveal Imager is designed to take the highest quality standardized and reproducible medical quality photographs. The system captures images of surface and sub-surface skin and will photograph front, left, and right views. The Reveal Imager is undergoing beta testing in Europe now and will be available in the spring.

A revolutionary new solution for professional skin care consultation, the elegant Reveal Imager was designed for the skin care counter, also making it ideal for spas, medical spas and traditional medical practices. With an easy-to-use and easy-to-learn interface anyone in a skin care office can take professional, repeatable facial photographs. The compact size and light weight also makes it ideal for traveling events, including health fairs.

The Reveal Imager uses the same Canfield proprietary RBX™ Technology employed in research laboratories and high-end skin care practices. With RBX, skin care professionals can detect subsurface vascular (red) and melanin (brown) conditions and develop highly targeted treatment recommendations. The system uses Canfield’s patent-pending IntelliFlash™ technology for both full spectrum and cross-polarized lighting modalities.

According to Doug Canfield, Founder and President of Canfield Imaging Systems, “Skin care professionals around the world asked Canfield to bring the elegance, ease of use, and reporting of market-leading VISIA® Complexion Analysis System to a broader set of businesses. Now, with the Reveal Imager, we can deliver a similar facial imaging experience to more customers and enhance their consultative process.”

The Reveal Imager is available in the US directly from Canfield Imaging Systems and outside the US through distributors worldwide.

ABOUT CANFIELD IMAGING SYSTEMS
Canfield Imaging Systems is a division of Canfield Scientific, Inc., which is the global leader in imaging systems services and products for scientific research and healthcare applications. Canfield Scientific, Inc serves the pharmaceutical, biotechnology, cosmetics, medical and skincare industries.

Canfield Imaging Systems utilizes the many years of experience and product breakthroughs of its parent company’s clinical research services, and tailors their products to the unique requirements of direct patient care in healthcare and wellness environments.

Canfield Imaging Systems
800.815.4330
www.canfieldsci.com

Source: Canfield Imaging Systems

PARIS and SCOTTSDALE, Ariz., (PRIME NEWSWIRE) — Medicis (NYSE:MRX) and Ipsen (Euronext:IPN) today announced that Ipsen has submitted a Biologics License Application (”BLA”) for the botulinum toxin type A, Reloxin(R) (Note 1), in aesthetic indications (glabellar lines) to the U.S. Food and Drug Administration’s (”FDA”) Division of Dermatology and Dental Products, within the Center for Drug Evaluation and Research. This BLA submission by Ipsen is intended to address the concerns cited by the FDA when it declined to file the Reloxin(R) BLA in January 2008, which Medicis had submitted in late 2007. Standard response timeframe from the FDA is expected approximately 10 months following receipt of the Reloxin(R) submission. Subject to approval of the BLA by the FDA, Medicis intends to commercialize Reloxin(R) in the U.S. in accordance with the long-standing arrangement between Medicis and Ipsen. Changes from the original BLA submission relate primarily to sponsorship and ownership of the filing. The substantive elements of the original submission remain unchanged.

Jean-Luc Belingard, Chairman and Chief Executive Officer of Ipsen, said: “We are pleased to have responded to the administrative issues raised by the FDA in coordination with Medicis in a timely and efficient manner. Together with Medicis, we look forward to working diligently with the FDA to obtain a successful marketing approval. Given Ipsen’s botulinum toxin positive track record on a global basis, we look forward to entering the North American market following FDA approval of Reloxin(R).”

“We are pleased to announce this submission of the BLA for Reloxin(R) in aesthetics with FDA,” said Jonah Shacknai, Chairman and Chief Executive Officer of Medicis. “Both the Ipsen and Medicis teams have worked diligently with FDA to determine the best solution for submitting Reloxin(R) in aesthetics. We thank everyone involved, and extend our appreciation to FDA for its willingness to work with us on a resolution in a timely fashion. We continue to believe the Reloxin(R) BLA is strong, and anticipate entering in the growing, multi-million dollar aesthetic botulinum toxin market in the U.S. upon FDA approval.”

In March 2006, Ipsen granted Medicis the rights to develop, distribute and commercialize Ipsen’s botulinum toxin product in the United States, Canada and Japan for aesthetic use by physicians. Upon FDA’s acceptance of the Reloxin(R) submission, Medicis will pay Ipsen approximately $25 million in accordance with the agreement between the parties.

According to the American Society for Aesthetic Plastic Surgery, injections of botulinum toxin type A were the number one non-surgical procedure in 2006, with over 3 million total procedures. Current growth estimates in botulinum toxin type A in dollars are estimated to be in excess of 20 percent over the prior year. This translates into a retail U.S. aesthetic market of approximately $300 million-$400 million (Note 2).

About Ipsen’s Botulinum Toxin Type A
As of October 2007, Ipsen’s botulinum toxin type A is approved for aesthetic indications in 21 countries: Argentina, Australia, Belarus, Brazil, Columbia, Ecuador, Egypt, Germany, Honduras, Israel, Kazakhstan, Mexico, Moldova, New Zealand, Philippines, Slovak Republic, Ukraine, Uruguay, Venezuela, Vietnam, and Russia (in Russia, it is the first botulinum toxin type A approved in this field). Ipsen is also pursuing regulatory approval for medical indications for the product in certain additional key international markets.
Dysport(R) is a neuromuscular blocking toxin which acts to block acetylcholine release, hence reducing muscular spasm, and was initially developed for the treatment of motor disorders and various forms of muscular spasticity, including cervical dystonia (a chronic condition in which the neck is twisted or deviated), spasticity of the lower limbs (heal) in children with cerebral palsy, blepharospasm (involuntary eye closure) and hemifacial spasm. It was later developed for the treatment of a wide variety of neuromuscular disorders and aesthetic medicine. Dysport(R) was originally launched in the United Kingdom in 1991 and has marketing authorisations in over 70 countries (at 31 December 2006). Ipsen has just recently filed a BLA for Dysport(R) in cervical dystonia to the FDA.

Medicis
www.medicis.com

Ipsen
www.ipsen.com

Source: Medicis

During the term of the prior Development and License Agreement, a home- use, light-based hair removal device for women was developed by Palomar together with Gillette. It is the first light-based aesthetic device to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA). OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. Designed specifically for use in the home and based on over a decade of research, this consumer device represents a major breakthrough in the aesthetic device industry.

In order to achieve FDA clearance, numerous clinical studies with over 600 subjects and thousands of treatments were conducted. These studies demonstrated that, when used as directed, the light-based device created under this agreement delivers comfortable, effective, skin-safe hair removal.

Stephanie Connaughton, Marketing Director, Global Grooming, said: “We are pleased that we were able to find a win-win outcome that enables continued work on this promising technology and increases the likelihood of commercial success.”

Commenting on this development, Palomar Chief Executive Officer Joseph P. Caruso said, “We strongly believe that we have developed game changing technology, and we look forward to seeing P&G’s products on the market. Over the past five years, Palomar and Gillette worked together to advance the technology and we have made tremendous progress in moving closer to penetrating the mass consumer market. Our biggest single achievement together has been penetrating the regulatory barrier to gain FDA approval of the first laser device for the home market.”

For more information, please see the non-exclusive License Agreement filed as Exhibit 10.1 to a Current Report on Form 8-K filed today, the Amended and Restated Development and License Agreement and Amendment #1 to the Amended and Restated Development and License Agreement filed as Exhibits 10.1 and 10.2 to a Current Report on Form 8-K filed February 21, 2007 and Amendment #2 to the Amended and Restated Development and License Agreement filed as Exhibit 10.1 to a current Report on Form 8-K filed December 21, 2007.

About Palomar Medical Technologies, Inc.
Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the- counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home use, light-based hair removal device. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets. In addition to the non- exclusive License Agreement with P&G, Palomar also has an agreement with Johnson & Johnson Consumer Companies to develop and potentially commercialize home-use, light-based devices for reducing or reshaping body fat including cellulite, reducing the appearance of skin aging, and reducing or preventing acne.

Palomar Medical Technologies, Inc.
781.993.2411
www.palomarmedical.com

Source: Palomar Medical Technologies, Inc.

- SmartSense(TM) for Smartlipo(TM): The World’s First Intelligent
Delivery System for Laser Lipolysis

- Accolade(TM): Cynosure’s Flagship Solution for the Removal of
Pigmented Lesions

- Affirm Er: An Ablative Energy Source that Expands the Affirm(TM)
Anti-Aging Workstation for Skin Resurfacing

Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, announced the introduction of three aesthetic products for fast-growing applications including laser lipolysis, the removal of pigmented lesions and ablative skin resurfacing. Cynosure will showcase its new products, SmartSense(TM) for Smartlipo(TM), Accolade(TM) and Affirm Er, at the American Academy of Dermatology (AAD) 2008 Annual Meeting, in San Antonio, Texas.

“Cynosure’s strategic vision is centered on the continuous improvement of aesthetic procedures through technology innovations that benefit patients and practitioners,” said Michael Davin, Cynosure’s president and chief executive officer. “Each of the products we are launching today fulfills that mission. Accolade, the sixth flagship product we have introduced in the past four years, creates exciting new revenue opportunities for us, particularly in markets throughout Asia, while SmartSense and Affirm Er enhance the benefits and performance of our two most recently introduced workstations.”

SmartSense for Smartlipo - Delivering Precise Energy Control to LaserBodySculpting
Recently FDA cleared, SmartSense is a proprietary intelligent handpiece delivery system for Smartlipo, Cynosure’s ground-breaking, minimally invasive system that liquefies and removes localized deposits of fat and results in tissue tightening through tissue coagulation. SmartSense features an advanced microchip, the Accelerometer, which is inserted into the intelligent handpiece, to ensure the precise level of energy is delivered based on the area of treatment and predetermined settings in conjunction with the motion of the handpiece.

“SmartSense provides our customers with an unparalleled degree of safety, precision and control that is not available with any other laser lipolysis technology,” Davin said. “Based on the setting you choose and the motion of the handpiece, SmartSense provides aesthetic surgeons with the precise laser power to perform laser lipolysis. To provide the maximum level of patient safety, if handpiece motion ceases SmartSense will stop the laser from firing, but remains ready and resumes firing once the handpiece is set in motion again.”

“SmartSense is an excellent addition to the Smartlipo workstation because it allows me to tailor the level of energy to the demands of the specific clinical indication,” said Barry Di Bernardo, M.D., medical director of New Jersey Plastic Surgery. “This not only helps to achieve a more consistent clinical outcome, but also adds an extra layer of safety and piece of mind for my patients. I look forward to incorporating the SmartSense into my laser lipolysis practice.”

Accolade - State-of-the-Art Technology to Remove Pigmented Lesions
Accolade is a high powered 755 nm, Q-switched Alexandrite laser for the removal of pigmented lesions. The unique combination of various spot sizes and the laser’s high repetition rates allow for rapid treatment. The initial target markets for Accolade will include Japan, Korea and China, where dermal lesions such as Nevus of Ota and Nevus of Ito are common.

“Given the market potential for this technology, particularly in the Asia Pacific region, we are excited about the prospects for Accolade,” Davin said. “As a flagship product, Accolade is expected to generate a minimum of $10 million in revenue in its first full year on the market.”

Affirm Er - Ablative Skin Resurfacing with Minimal Downtime
Cynosure’s new Affirm Er is a 2940 nm wavelength, Erbium: YAG laser for ablative skin resurfacing applications, such as the treatment of deep lines and wrinkles. The Affirm Er handpiece is designed as a complementary fourth wavelength for the Affirm Anti-Aging workstation, Cynosure’s award-winning platform for anti-aging applications such as skin rejuvenation, wrinkles, skin discoloration and tissue tightening.

“With the introduction of Affirm Er, we are responding to growing demand for an ablative technology that best addresses the treatment of deep lines and wrinkles,” Davin said. “Since its introduction a year ago, our innovative Affirm workstation has been enthusiastically received by the marketplace, both in the U.S. and overseas. By adding the Erbium wavelength, we are further increasing the versatility, flexibility and cost-effectiveness of Affirm for our customers.”

Bruce E. Katz, M.D., director of the Juva Skin & Laser Center, said, “For our patients, the Affirm system has been extremely effective in the treatment of wrinkles and scars, while tightening the underlying tissue. Some patients want a more rapid therapy for deep lines and wrinkles. The addition of this ablative component expands Affirm’s ability to address the anti-aging marketplace.”

According to the Millennium Research Group, the skin rejuvenation market is expected to grow annually by 18 percent, resulting in a $239 million industry by 2010, with approximately 4.4 million procedures performed per year by 2010.

About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure’s products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light.

Cynosure, Inc.
800.886.2966
www.cynosure.com

Source: Cynosure, Inc.

WAYLAND, Mass.–(BUSINESS WIRE)–March 10, 2008–Candela Corporation (NASDAQ: CLZR) announced today that Robert LaRoche has joined the company as Vice President of Global Marketing. Mr. LaRoche will lead Candela’s worldwide marketing efforts of current products and pipeline product opportunities.

“With over 25 years of medical device marketing and sales experience, Bob is a proven leader in the medical device marketplace. We are confident that he will apply his unique skill set and insight to drive sales revenues and increase global awareness of Candela’s products,” said Jay Caplan, Chief Operating Officer.

Most recently, Mr. LaRoche served as Vice President of Marketing and Sales at InfraReDx, Inc., a Burlington, Massachusetts-based medical device start-up, where he led the marketing and sales development process for the company’s first commercialized product. Prior to that, he was Founder and President of Octant Marketing Inc., a consultancy serving the medical products industry, and has also held various managerial marketing positions.

Mr. LaRoche earned a Bachelor’s degree in Marine Fisheries Biology from the University of Massachusetts Amherst.

About Candela
Candela Corporation manufactures, and distributes innovative clinical solutions that enable physicians, surgeons, and personal care practitioners to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Founded near Boston in 1970, the company markets and services its products in over 70 countries from offices and distributors in the United States, Europe, Japan, China and other Asian locations. Candela established the aesthetic laser market 18 years ago, and currently has an installed base of an estimated 12,000 lasers worldwide.

Candela Corporation
800.733.8550
www.candelalaser.com

Source: Candela Corporation

HAYWARD, Calif., March 12 /PRNewswire-FirstCall/ — Thermage, Inc. (Nasdaq: THRM), a leader in non-invasive tissue tightening in the aesthetic industry, today announced it has begun initial shipments of its ThermaTip(TM) CL treatment tips for use in the Company’s cellulite procedure. The procedure noticeably reduces the appearance of cellulite after just a single treatment. The treatment tip and procedure are the result of 21 months of clinical and technological development and use the FDA cleared ThermaCool(R) system for the temporary improvement in the appearance of cellulite.

“We began shipments of our ThermaTip CL treatment tip on track and within the timeframe we expected,” said Stephen J. Fanning, Chairman of the Board, President and Chief Executive Officer at Thermage. “Cellulite offers a new market opportunity for our Company and we expect the new tip to provide a solid contribution to our revenue in 2008.”

The ThermaTip CL and cellulite procedure by Thermage incorporate the Company’s patented monopolar capacitive radiofrequency technology. The advanced deep heating ThermaTip CL rebuilds collagen connective tissues and improves blood flow to the tissue helping to smooth the appearance of the skin’s surface.

About Thermage, Inc.
Thermage’s innovative technology provides a unique non-invasive procedure designed to tighten and contour skin, significantly expanding the non-invasive aesthetic applications physicians can offer to the rapidly growing “anti- aging” market.

Thermage, Inc.
510.259.7117
www.thermage.com

Source: Thermage, Inc.

Peers, friends and colleagues can nominate healthcare professionals demonstrating exceptional service, sacrifice and innovation March 1 – May 31, 2008

Los Angeles, March 10, 2008 – Six years have passed since Cherokee Uniforms first began recognizing healthcare professionals through its Inspired Comfort Awards program. Since that time, the leading designer and manufacturer of healthcare apparel has awarded nearly 60 healthcare professionals from across the country for their exceptional service, sacrifice and innovation. Although winners have had diverse backgrounds, all of them have one thing in common—a sincere passion for bettering the lives of others.

Nominations are being accepted March 1 – May 31, 2008 for this year’s awards program. The program provides a meaningful way for peers, friends and colleagues to acknowledge healthcare professionals for their significant contributions to patients and medical care.

“The nominations that we have received throughout the years are a true testament to the immense dedication that healthcare professionals display on a daily basis,” said Michael Singer, president and CEO of Cherokee Uniforms. “We are proud to recognize those individuals who have made the healthcare industry what it is today by providing care and compassion to their patients at times when they need it the most.”

To nominate a healthcare professional, visit www.CherokeeUniforms.com or pick up a nomination form from a Cherokee Uniforms retailer. Candidates may be nominated in two of the following categories but can only win in one: Registered Nurses (RNs); Advanced Practice Nurses (APNs); Licensed Practical Nurses/Licensed Vocational Nurses (LPNs/LVNs); Students enrolled in schools of nursing; and other Non-Physician Healthcare Professionals.

Nominations must contain an accurate description (100 words or more) of the candidate’s exceptional service, sacrifice or innovation. Random drawings will be held during March, April and May, giving nominators a chance to win prizes, such as an iPod or a set of Cherokee scrubs. Additionally, all nominators will receive a gold pin etched with the award’s emblem.

Cherokee Uniforms will make a donation for every healthcare professional who is nominated for the award through May 31, 2008, to Nurses House, a national fund that provides short-term financial assistance to registered nurses facing serious hardship.

A panel of nurse leaders, Cherokee professionals and former award recipients will choose winners who best meet the program’s criteria: exceptional service, sacrifice and innovation.

The grand prize winner in each category will receive an all-expense-paid Caribbean cruise for two. Additional winners in each category will receive all-expense-paid trips to a 2009 U.S. medical conference of each winner’s choice, an annual membership to their preferred clinical association and a donation of $500 to the nonprofit organization of their choice.

Every award winner will receive a trophy, a medical wardrobe of Cherokee scrubs and Rockers footwear worth more than $1,000, and a profile in the nationally distributed Cherokee Inspired Comfort Award 2009 calendar. Additionally, those who nominated the grand prize winner in each category will each receive a Cherokee medical wardrobe and a donation of $500 to the nonprofit organization of their choice. Nominations are due by May 31, 2008. Winners will be announced in September 2008.

About Cherokee
Cherokee Uniforms, Tooniforms and Rockers Footwear are leading brands in healthcare apparel, recognized for helping to foster a warmer, friendlier, more comfortable environment for healthcare workers and their patients.

Cherokee Uniforms
818.671.2100
www.CherokeeUniforms.com